Teacher:In this task, you are given a text of many news articles seperated by special token "|||||". Your task is to summarize them.
Teacher: Now, understand the problem? Solve this instance: A new leukemia immune treatment being developed by Novartis AG (NOVN) led to the disappearance of cancer in 90 percent of patients, a study showed. 
  
 The therapy, a process that involved taking a patient’s T cells and reprogramming them to hunt cancer cells, resulted in complete remission of 27 of 30 patients with acute lymphoblastic leukemia, a deadly pediatric cancer, according to the study published today by the New England Journal of Medicine. 
  
 The early-stage trial of CTL019 engineered cells conducted by researchers at the University of Pennsylvania indicates the potential of the complicated treatment, which analysts have estimated may generate $10 billion a year if its uses expand beyond leukemia. The therapy can provoke serious side affects, however, and eight of the 30 patients required intensive care for severe cytokine-release syndrome. 
  
 “We are excited by these results, which indicated how effective CTL019 may be in fighting ALL, a leading cause of childhood cancer deaths,” said lead investigator Stephan Grupp, a professor at the university. 
  
 Immune therapies, which harness the body’s own defense system to fight cancer and other diseases, have taken the pharmaceutical industry by storm, with analysts estimating $35 billion in annual sales. Unlike products on the market such as Bristol-Myers Squibb Co. (BMY)’s Yervoy, CTL019 therapy involves removing a patient’s blood to modify their blood cells. 
  
 Breakthrough Therapy 
  
 The published study updated trial data first reported in December at the American Society of Hematology’s annual meeting. A further update will be released at this year’s meeting. 
  
 The therapy is now in the second of three stages of human trials for acute lymphoblastic leukemia, with studies for other forms of cancer planned for next year. Novartis, based in Basel, Switzerland, received a breakthrough therapy designation from the U.S. Food and Drug Administration in July. The company will seek FDA approval in 2016. 
  
 Patients in the trial -- 25 children and five adults -- received infusions between April 2012 and February of this year. Of the 27 patients who were successfully treated, 19 remained in remission and 15 of them received no further therapy. Seven patients died after a relapse of the disease. 
  
 In 2013, more than 43,000 adults and 5,000 children and teens in the U.S. were diagnosed with leukemia, with about 6,000 having acute lymphoblastic leukemia. 
  
 To contact the reporter on this story: Oliver Staley in London at ostaley@bloomberg.net 
  
 To contact the editors responsible for this story: Phil Serafino at pserafino@bloomberg.net Kristen Hallam, Bruce Rule ||||| NEW YORK (Reuters Health) - Ninety percent of people facing death because conventional treatments had failed to destroy their leukemia have responded to an experimental therapy that trains their cells to kill out-of-control blood cells, doctors in Philadelphia report. 
  
 Twenty seven of the 25 children and 5 adults initially responded to the new therapy. Nineteen - including a 9-year-old treated two and a half years ago - have remained cancer-free and 15 of those 19 have not receive any subsequent therapy. 
  
 "We're astonished how well it turned out," senior author Dr. Stephan Grupp of Children's Hospital of Philadelphia told Reuters Health. Doctors are often happy if a treatment can improve the remission rate by 3 percent to 5 percent. "In our wildest dreams, we didn't think it would work as well as it did for the patients we've treated so far," Grupp said. 
  
 "It's equally impressive in both the adult and pediatric population," said Dr. Noelle Frey of the University of Pennsylvania, who directed the adult portion of the study. 
  
 "These are patients where the chances of cure are close to zero, if not zero," she said. "This is a therapy that not only gives hope, but is also correlated with tremendous success." 
  
 The treatment results, reported in the New England Journal of Medicine, are part of a broader effort to reprogram the cells of cancer patients so they reproduce rapidly and attack the rogue cells responsible for tumors. 
  
 "If this has curative potential - which we don't know yet, but seems to be the case - it's a game changer," said Dr. Michael Sadelain of Memorial Sloan Kettering Cancer Center, part of a separate team that previously used the technique to produce complete remissions in 14 out of 16 adults who had acute lymphoblastic leukemia (ALL) of a stage "where nobody would go into complete remission." 
  
 "The good news is, this therapy can work just as well in children as it was reported to do in adults," he told Reuters Health. 
  
 In the Philadelphia study, other treatments - as many as four - had failed in the 30 patients. Conventional therapy typically cures 80 percent to 85 percent of children with ALL and those children "don't need this," said Grupp. "The other 15 percent or so are candidates for this." 
  
 Adults with ALL are tougher to treat, "so 50 percent or more might need this," he said. 
  
 In July, the U.S. Food and Drug Administration gave the treatment, known as CTL019, a Breakthrough Therapy designation designed to expedite its development for ALL. 
  
 The Philadelphia researchers have also been experimenting with CTL019 for chronic lymphocytic leukemia and Hodgkin's lymphoma,. The remission rates in those tests have been high, but not nearly as high as with ALL, Frey told Reuters Health. Those findings have not been published. 
  
 The ALL treatment involves training disease-fighting blood cells known as T-cells. Once removed from a patient's body, they are programmed to hunt cancer cells that have a telltale protein on their surface. The specially-trained cells are then re-injected into the patient. The re-engineering process currently costs about $25,000. 
  
 Of the initial 30 patients, 27 were in complete remission by the one-month mark, but seven relapsed over a period ranging from 6 weeks to 8.5 months after treatment. Twenty three were alive at the six-month mark. Five of the 23 left the study to receive other treatments, including stem cell transplantation. 
  
 The treatment is not without serious risks. The most common is cytokine release syndrome, where the body appears to react to the mass killing of tumor cells. 
  
 Patients "become tired, achy and nauseous," said Frey. "You can also get low blood pressure and breathing difficulties. Unfortunately, it can be life-threatening. But we have, in most cases, been able to reverse it. Yet in most situations it’s very manageable." 
  
 “For our patients who have already relapsed after stem cell transplants, or don’t have any options for donors," she said, "this option has provided new hope.” 
  
 In eight of the 27 cases where there was a response, cytokine release syndrome was judged to be severe and the patients ended up in intensive care. 
  
 At least part of the technique involved in the Philadelphia study has been licensed to Novartis. Sloan Kettering has teamed up with a start-up company, Juno Therapeutics, which will conduct a multicenter study of adults with ALL, Sadelain said. 
  
 "That's a sea change in the field because, until now, this realm of cell therapy was almost exclusively in the hands of academic centers," he said. "Now you see a whole host of companies moving into this space. Investors have been impressed by these results and will take them far beyond what academic centers will do." 
  
 SOURCE: bit.ly/1syxUeI New England Journal of Medicine, October 15, 2014. |||||
Student:
An experimental therapy labeled the "holy grail" of cancer treatment a few years ago has produced amazing results in a group of leukemia patients who had been given a few months or even a few weeks to live, researchers say. Some 30 patients with an acute form of leukemia were given the treatment, which "trains" a patient's immune cells to kill rogue cells and spawn more cancer-killing cells. Of those, all but three went into remission, and 23 were still alive six months or more later. Multiple other treatments had failed in the five adults and 25 children and young adults who received the treatment. Seven of those who got the treatment have since died, but 19 are still cancer-free, including 15 who have had no other treatment, reports the New York Times. "We're astonished how well it turned out," a researcher at the Children's Hospital of Philadelphia tells Reuters, which notes that a 3% improvement in the remission rate is considered a success for a new therapy, while this one achieved a stunning 90%. "In our wildest dreams, we didn't think it would work as well as it did for the patients we've treated so far." The treatment has its drawbacks—serious side effects put eight of the patients in intensive care, reports Bloomberg—but researchers say the latest trial proves early successes were no fluke and that the treatment holds promise for fighting other kinds of cancer. (Another experimental cancer treatment involves bee venom.)